Johnson & Johnson vs Pfizer JNJ vs PFE
Johnson & Johnson and Pfizer on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Return on equity: Johnson & Johnson 24.8%, Pfizer 5.1%.
- Market value: Johnson & Johnson $615.87B, Pfizer $168.60B.
- Net margin: Johnson & Johnson 21.5%, Pfizer 6.8%.
- Price / sales: Johnson & Johnson 6.3×, Pfizer 2.6×.
Price return
2025-10-16 → 2026-10-16
JNJ+33.0%
PFE+22.1%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$615.87B
$168.60B
Enterprise value
$644.49B
$230.81B
Employees
141,700
75,000
Revenue per employee (TTM)
$691K
$849K
Our models
nightlythe valuation on each stock's pagePrice vs model
36% undervalued vs model
3% undervalued vs model
Model range
$231–839
$12.41–64.63
Models in the headline
1
1
FCF growth priced in, at a 10% return
18.6%
14.0%
Every model, its assumptions and its range: JNJ valuation · PFE valuation. The growth priced in, at any return: JNJ reverse DCF · PFE reverse DCF.
Trading
close 2026-10-16Last close
$255.56
$29.58
52-week high
$278.43
$29.58
52-week low
$186.00
$23.67
Price vs 52-week high
−8.2%
0.0%
Price vs 52-week low
+37.4%
+25.0%
Average daily volume / shares
0.3%
0.7%
Beta
0.23
0.28
Returns
to 2026-10-161 month
−4.4%
+7.7%
3 months
+2.2%
+17.7%
6 months
+9.0%
+8.7%
Year to date
+23.5%
+18.8%
1 year
+33.0%
+22.1%
1 year, dividends added
+35.8%
+29.2%
2 years
+55.6%
−0.3%
Valuation
price × TTM to Jun 2026P/E (TTM)
29.7×
38.9×
P/E on consensus EPS (next FY)
22.8×
10.0×
Price / sales
6.3×
2.6×
EV / sales
6.6×
3.6×
EV / EBITDA
—
—
Price / book
7.2×
2.0×
Price / free cash flow (FY)
31.3×
18.6×
Free-cash-flow yield (FY)
3.2%
5.4%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+7.5%
−0.5%
Revenue, 3-year CAGR
−0.3%
−12.0%
Revenue, 5-year CAGR
2.7%
8.3%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+1.4%
+117.7%
EPS, 3-year CAGR
17.9%
−37.1%
Free cash flow, 3-year CAGR
4.7%
−29.6%
Diluted shares, 3-year change
−8.8%
−0.3%
Profitability
TTM to Jun 2026Gross margin (FY)†
67.9%
70.3%
Operating margin
—
—
EBITDA margin
—
—
Net margin
21.5%
6.8%
Free-cash-flow margin (FY)
20.9%
14.5%
Return on equity
24.8%
5.1%
Return on assets
10.5%
2.2%
Asset turnover
0.49
0.32
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Jun 2026Cash
$20.42B
$976.0M
Total debt
$49.04B
$63.19B
Net debt
$28.61B
$62.22B
Debt / equity
0.6×
0.7×
Net debt / EBITDA (TTM)
—
—
Interest coverage (FY)
26.4×
5.8×
Current ratio (FY)
1.03
1.16
Dividends
trailing 12 monthsDividend yield
2.1%
5.8%
Dividends per share
$5.28
$1.72
Payout ratio (of TTM EPS)
61.3%
226.3%
Dividend per share, 5-year CAGR
5.0%
2.1%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
15
11
Insider open-market buys (Form 4)
$0
$3.0M
Insider sales (Form 4)
$67.8M
$83K
Analyst upgrades
0
0
Analyst downgrades
0
0
Statements
income TTM to Jun 2026 · cash flow FY2025Revenue
$97.93B
$63.70B
EBITDA
—
—
Operating income
—
—
Net income
$21.04B
$4.33B
EPS (diluted)
$8.61
$0.76
Operating cash flow
$24.53B
$11.70B
Capital expenditure
−$4.83B
−$2.63B
Free cash flow
$19.70B
$9.07B
Dividends paid
—
—
Keep comparing
Johnson & Johnson against
Pfizer against
Statements from the companies' SEC filings; prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.